High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autoren

  • Torben Schweer
  • Wilfried Gwinner
  • Irina Scheffner
  • Anke Schwarz
  • Hermann Haller
  • Cornelia Blume

Externe Organisationen

  • Medizinische Hochschule Hannover (MHH)
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Seiten (von - bis)512-519
Seitenumfang8
FachzeitschriftClinical Transplantation
Jahrgang28
Ausgabenummer4
Frühes Online-Datum21 März 2014
PublikationsstatusVeröffentlicht - Apr. 2014
Extern publiziertJa

Abstract

Although major risk factors for post-transplant diabetes (PTDM) after kidney transplantation have been identified, a systematic study on the impact of rejection and rejection therapy is missing so far. Methods: Five hundred and twenty-six kidney transplant recipients transplanted in the years 2000-2007 were included. PTDM was defined according to WHO guidelines, and patients' data were compared with special attention to protocol and for cause biopsies and rejection therapies. Survival analyses were made for graft loss and patient death. Results: 16.7% of all patients developed PTDM. Among common risk factors as higher age, body mass index (BMI), and others, the factor "acute cellular rejections" was comparably most relevant with a hazard ratio of 3.7. Consequently, antirejective treatment with steroid pulses and conversion to tacrolimus was the factor with the highest relative risk for the onset of PTDM (RR 3.5). PTDM itself had no impact on graft or patients' survival, but the decreased graft survival in PTDM patients was dominantly influenced by the higher frequency of acute cellular rejections, and patients' survival was reduced due to higher age. Conclusion: Based upon a higher rate of acute rejections (AR), the necessity of frequent antirejective treatments was more relevant for the induction of PTDM than age or BMI.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. / Schweer, Torben; Gwinner, Wilfried; Scheffner, Irina et al.
in: Clinical Transplantation, Jahrgang 28, Nr. 4, 04.2014, S. 512-519.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Schweer T, Gwinner W, Scheffner I, Schwarz A, Haller H, Blume C. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. Clinical Transplantation. 2014 Apr;28(4):512-519. Epub 2014 Mär 21. doi: 10.1111/ctr.12329
Schweer, Torben ; Gwinner, Wilfried ; Scheffner, Irina et al. / High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. in: Clinical Transplantation. 2014 ; Jahrgang 28, Nr. 4. S. 512-519.
Download
@article{c0ce03f0cb314c16be810a9ebaf4913c,
title = "High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation",
abstract = "Although major risk factors for post-transplant diabetes (PTDM) after kidney transplantation have been identified, a systematic study on the impact of rejection and rejection therapy is missing so far. Methods: Five hundred and twenty-six kidney transplant recipients transplanted in the years 2000-2007 were included. PTDM was defined according to WHO guidelines, and patients' data were compared with special attention to protocol and for cause biopsies and rejection therapies. Survival analyses were made for graft loss and patient death. Results: 16.7% of all patients developed PTDM. Among common risk factors as higher age, body mass index (BMI), and others, the factor {"}acute cellular rejections{"} was comparably most relevant with a hazard ratio of 3.7. Consequently, antirejective treatment with steroid pulses and conversion to tacrolimus was the factor with the highest relative risk for the onset of PTDM (RR 3.5). PTDM itself had no impact on graft or patients' survival, but the decreased graft survival in PTDM patients was dominantly influenced by the higher frequency of acute cellular rejections, and patients' survival was reduced due to higher age. Conclusion: Based upon a higher rate of acute rejections (AR), the necessity of frequent antirejective treatments was more relevant for the induction of PTDM than age or BMI.",
keywords = "Immunosuppressive therapy, PTDM, Rejection therapy, Renal transplant biopsies",
author = "Torben Schweer and Wilfried Gwinner and Irina Scheffner and Anke Schwarz and Hermann Haller and Cornelia Blume",
year = "2014",
month = apr,
doi = "10.1111/ctr.12329",
language = "English",
volume = "28",
pages = "512--519",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

Download

TY - JOUR

T1 - High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation

AU - Schweer, Torben

AU - Gwinner, Wilfried

AU - Scheffner, Irina

AU - Schwarz, Anke

AU - Haller, Hermann

AU - Blume, Cornelia

PY - 2014/4

Y1 - 2014/4

N2 - Although major risk factors for post-transplant diabetes (PTDM) after kidney transplantation have been identified, a systematic study on the impact of rejection and rejection therapy is missing so far. Methods: Five hundred and twenty-six kidney transplant recipients transplanted in the years 2000-2007 were included. PTDM was defined according to WHO guidelines, and patients' data were compared with special attention to protocol and for cause biopsies and rejection therapies. Survival analyses were made for graft loss and patient death. Results: 16.7% of all patients developed PTDM. Among common risk factors as higher age, body mass index (BMI), and others, the factor "acute cellular rejections" was comparably most relevant with a hazard ratio of 3.7. Consequently, antirejective treatment with steroid pulses and conversion to tacrolimus was the factor with the highest relative risk for the onset of PTDM (RR 3.5). PTDM itself had no impact on graft or patients' survival, but the decreased graft survival in PTDM patients was dominantly influenced by the higher frequency of acute cellular rejections, and patients' survival was reduced due to higher age. Conclusion: Based upon a higher rate of acute rejections (AR), the necessity of frequent antirejective treatments was more relevant for the induction of PTDM than age or BMI.

AB - Although major risk factors for post-transplant diabetes (PTDM) after kidney transplantation have been identified, a systematic study on the impact of rejection and rejection therapy is missing so far. Methods: Five hundred and twenty-six kidney transplant recipients transplanted in the years 2000-2007 were included. PTDM was defined according to WHO guidelines, and patients' data were compared with special attention to protocol and for cause biopsies and rejection therapies. Survival analyses were made for graft loss and patient death. Results: 16.7% of all patients developed PTDM. Among common risk factors as higher age, body mass index (BMI), and others, the factor "acute cellular rejections" was comparably most relevant with a hazard ratio of 3.7. Consequently, antirejective treatment with steroid pulses and conversion to tacrolimus was the factor with the highest relative risk for the onset of PTDM (RR 3.5). PTDM itself had no impact on graft or patients' survival, but the decreased graft survival in PTDM patients was dominantly influenced by the higher frequency of acute cellular rejections, and patients' survival was reduced due to higher age. Conclusion: Based upon a higher rate of acute rejections (AR), the necessity of frequent antirejective treatments was more relevant for the induction of PTDM than age or BMI.

KW - Immunosuppressive therapy

KW - PTDM

KW - Rejection therapy

KW - Renal transplant biopsies

UR - http://www.scopus.com/inward/record.url?scp=84899127866&partnerID=8YFLogxK

U2 - 10.1111/ctr.12329

DO - 10.1111/ctr.12329

M3 - Article

C2 - 24649873

AN - SCOPUS:84899127866

VL - 28

SP - 512

EP - 519

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -

Von denselben Autoren